Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) and Histogen Inc., a privately-held regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced Tuesday the companies have entered into a definitive agreement under which Histogen will merge with a wholly-owned subsidiary of Conatus in an all-stock transaction. The combined company will operate under the name Histogen, Inc., is expected to trade on the Nasdaq Capital Market under a new ticker symbol still to be determined and will focus on advancement of its patented technology for dermatological and orthopedic indications.
Read the full article: Conatus Pharmaceuticals and Histogen Enter into Definitive Merger Agreement //
Source: https://www.globenewswire.com/news-release/2020/01/28/1976385/0/en/Conatus-Pharmaceuticals-and-Histogen-Enter-into-Definitive-Merger-Agreement.html